For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib ...

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...

CytomX Therapeutics' innovative cancer therapies show promise with the CX-2051 and CX-801 trials. Explore the potential of ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Eftilagimod alfa shows promise as a novel immunotherapy for head and neck cancer patients with low PD-L1 expression, offering ...

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.

Pembrolizumab is also approved as first-line treatment in cisplatin-ineligible patients with high PD-L1 expression. 9 - 11 Integrating short courses of pre-RC immunotherapy in nonmetastatic MIBC has ...